The Impact of Berberine as an Adjunct Therapy on Hormonal, Metabolic, and Inflammatory Outcomes in Women Diagnosed with Polycystic Ovary Syndrome: A Retrospective Case-Control Analysis

Category	Detail
Condition
Key Mechanisms	Insulin resistance, androgen excess, low-grade inflammation, and their impact on metabolic and reproductive health.
Target Population
Care Setting

Berberine combined with progesterone showed significant reductions in weight, BMI, and WHR, with adjusted between-group differences becoming significant.
Total testosterone levels decreased significantly in the berberine group, indicating a superior effect.
Fasting insulin, FBS, and HOMA-IR improved significantly in the berberine group compared to controls.
Inflammatory markers (CRP, TNF-α, IL-6) declined significantly only in the berberine group, with significant between-group differences.
Adjunctive berberine therapy may improve metabolic and inflammatory profiles in PCOS, warranting further investigation.

Monitor anthropometric (weight, BMI, WHR), hormonal (testosterone, insulin), metabolic (FBS, HOMA-IR), and inflammatory (CRP, TNF-α, IL-6) outcomes during treatment.

Berberine may enhance the effects of progesterone on metabolic and inflammatory parameters; consider potential side effects.

Integrate metabolic and inflammatory assessments in the management of PCOS.
Evaluate the potential benefits of adjunctive therapies like berberine in clinical practice.
Consider follow-up assessments at 3 and 6 months post-treatment to evaluate long-term effects.

Clinical Scorecard: The Impact of Berberine as an Adjunct Therapy on Hormonal, Metabolic, and Inflammatory Outcomes in Women Diagnosed with Polycystic Ovary Syndrome: A Retrospective Case-Control Analysis